How to buy CohBar stock

CohBar, Inc is a biotechnology business based in the US. CohBar shares (CWBR) are listed on the NASDAQ and all prices are listed in US Dollars. CohBar employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

CohBar share price

Use our graph to track the performance of CWBR stocks over time.

CohBar shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$0.88 - $4.25
50-day moving average	$1.36
200-day moving average	$1.36
Wall St. target price	$5.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.35

Buy CohBar shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy CohBar stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of CohBar, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CohBar financials

Gross profit TTM	$0
Return on assets TTM	-46.56%
Return on equity TTM	-122.18%
Profit margin	0%
Book value	$0.30
Market capitalisation	$80.9 million

TTM: trailing 12 months

Shorting CohBar shares

There are currently 2.9 million CohBar shares held short by investors – that's known as CohBar's "short interest". This figure is 7.9% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting CohBar shares can be evaluated.

CohBar's "short interest ratio" (SIR)

CohBar's "short interest ratio" (SIR) is the quantity of CohBar shares currently shorted divided by the average quantity of CohBar shares traded daily (recently around 590587.70491803). CohBar's SIR currently stands at 4.88. In other words for every 100,000 CohBar shares traded daily on the market, roughly 4880 shares are currently held short.

However CohBar's short interest can also be evaluated against the total number of CohBar shares, or, against the total number of tradable CohBar shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CohBar's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 CohBar shares in existence, roughly 50 shares are currently held short) or 0.0604% of the tradable shares (for every 100,000 tradable CohBar shares, roughly 60 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CohBar.

Find out more about how you can short CohBar stock.

CohBar share dividends

We're not expecting CohBar to pay a dividend over the next 12 months.

CohBar share price volatility

Over the last 12 months, CohBar's shares have ranged in value from as little as $0.875 up to $4.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CohBar's is 2.8125. This would suggest that CohBar's shares are significantly more volatile than the average for this exchange and represent a higher risk.

CohBar overview

CohBar, Inc. , a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Frequently asked questions

• What percentage of CohBar is owned by insiders or institutions?

  Currently 23.448% of CohBar shares are held by insiders and 13.347% by institutions.

• How many people work for CohBar?

  Latest data suggests 11 work at CohBar.

• When does the fiscal year end for CohBar?

  CohBar's fiscal year ends in December.

• Where is CohBar based?

  CohBar's address is: 1455 Adams Drive, Menlo Park, CA, United States, 94025

• What is CohBar's ISIN number?

  CohBar's international securities identification number is: US19249J1097

• What is CohBar's CUSIP number?

  CohBar's Committee on Uniform Securities Identification Procedures number is: 19249J109